By contrast, astegolimab, a human mAb that inhibits the IL-33 receptor serum stimulation-2 (ST2), did not significantly improve FEV1 after 54 weeks of treatment in patients with severe asthma, although exacerbations were reduced [174]. The gene discussed is IL1RL1; the disease is asthma.